Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GelStat Breaks Into Retail With Migraine Remedy

This article was originally published in The Tan Sheet

Executive Summary

CEO Larry Gershman says GelStat will launch a marketing campaign to support extending its products for the first time to retail stores. The firm changed its sublingual migraine homeopathic to a single dose from two doses taken five minutes apart.

You may also be interested in...



Industry News Roundup

Natural Alternatives International sales increase; Fresh Promise Foods secures funding; Youngevity expands supplement portfolio; GelStat expands convenience store distribution; U.S. Marshals seize kratom; Herbal Vigor, Arize are adulterated; and lead found in children’s product.

Industry News Roundup

Natural Alternatives International sales increase; Fresh Promise Foods secures funding; Youngevity expands supplement portfolio; GelStat expands convenience store distribution; U.S. Marshals seize kratom; Herbal Vigor, Arize are adulterated; and lead found in children’s product.

Novartis Turns To OTC Co-Packers As Lincoln Plant Lags

Originally expected back online by the summer, the Novartis Consumer Health facility in Lincoln, Neb., will not ship any product in 2012. Novartis, which reported consumer sales down 22% to $938 million in Q3, is using third-party manufacturers to restore Excedrin Migraine and other OTCs to market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel